VIROPTIC
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VIROPTIC (VIROPTIC).
Trifluridine is a fluorinated pyrimidine nucleoside analogue that inhibits viral DNA replication by incorporating into viral DNA and inhibiting thymidylate synthetase.
| Metabolism | Primarily metabolized via thymidine phosphorylase and other nucleoside-metabolizing enzymes; systemic metabolism is minimal due to topical application. |
| Excretion | Renal excretion of unchanged drug and metabolites; approximately 70% of a dose is recovered in urine within 24 hours. Biliary/fecal elimination accounts for less than 10%. |
| Half-life | Terminal elimination half-life is approximately 2.5 hours in adults with normal renal function. In patients with renal impairment, half-life may be prolonged, requiring dose adjustment. |
| Protein binding | Protein binding is approximately 15-20%, primarily to albumin. |
| Volume of Distribution | Volume of distribution is approximately 0.5 L/kg, indicating distribution into total body water. |
| Bioavailability | Systemic bioavailability following ophthalmic administration is minimal (less than 5%) due to low corneal penetration and rapid dilution by tears; not administered orally or parenterally. |
| Onset of Action | For ophthalmic administration, clinical improvement is typically observed within 2 to 4 days of initiating therapy. |
| Duration of Action | Duration of action is approximately 4 to 6 hours after topical ophthalmic administration. Frequent dosing (e.g., every 1-2 hours) is required initially. |
| Molecular Weight | 296.2 |
1 drop of 1% solution into the affected eye every 2 hours while awake, up to 9 drops per day, for 7-21 days.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dose adjustment required; negligible systemic absorption following topical ocular administration. |
| Liver impairment | No dose adjustment required; negligible systemic absorption following topical ocular administration. |
| Pediatric use | Same as adult dosing: 1 drop of 1% solution into the affected eye every 2 hours while awake, up to 9 drops per day, for 7-21 days. |
| Geriatric use | Same as adult dosing; no specific elderly considerations beyond standard monitoring for ocular effects. |
| 1st trimester | Trifluridine (VIROPTIC) is an ophthalmic antiviral. No adequate human studies exist; animal studies not performed. Use only if potential benefit outweighs risk. Embryotoxic in animals at high doses. |
| 2nd trimester | Limited data; systemic absorption is minimal after ophthalmic use, but caution advised. Risk vs. benefit assessment required. |
| 3rd trimester | As trimester 2. Minimal systemic absorption expected, but no data on third trimester effects. |
Clinical note
Comprehensive clinical and safety monograph for VIROPTIC (VIROPTIC).
| Placental transfer | Not studied in humans; likely minimal due to ophthalmic route and low systemic levels. Animal studies indicate trifluridine can cross placenta, but relevance uncertain. |
| Breastfeeding | Systemic absorption after ophthalmic administration is negligible, but no data on excretion in human milk. Caution advised; consider discontinuing breastfeeding or the drug, weighing importance to mother. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to trifluridine or any component of the formulation
| Precautions | May cause local irritation, burning, stinging, or edema., Prolonged use may lead to corneal epithelial toxicity or scarring., Not for use in herpes simplex virus infections involving the corneal stroma or uveal tract. |
| Food/Dietary | No known food interactions. Avoid alcohol if driving due to temporary blurred vision. |
| Clinical Pearls | Trifluridine (VIROPTIC) is a topical antiviral for herpes simplex keratitis. Initiate therapy early; 1 drop q2h while awake (max 9 drops/day) for acute infection, then taper. Avoid prolonged use beyond 21 days to prevent corneal toxicity. Re-evaluate if no improvement after 7 days. Does not treat stromal disease or iritis without epithelial involvement. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Pregnancy Category C. Animal reproduction studies have shown embryotoxicity and teratogenicity at high doses. No adequate human studies. Risk cannot be ruled out; use only if clearly needed. |
| Fetal Monitoring | Monitor for ocular adverse effects (e.g., corneal epithelial defects, punctate keratitis) and systemic absorption. No specific fetal monitoring required but pregnancy testing may be considered. |
| Fertility Effects | No adequate fertility studies in humans. In animal studies, no impairment of fertility observed. |
| Patient Advice | Do not touch dropper tip to eye or any surface to avoid contamination. · Apply exactly as prescribed; do not skip doses or stop early. · Mild stinging or burning is common; report severe pain, vision changes, or worsening redness. · Wash hands before and after use; wait 5 minutes between different eye drops. · Remove contact lenses during treatment and discard if used while infected. · Use separate towel and wash hands frequently to avoid spreading infection. |